21,388 named.
4,484 in your entry pool.

Your three tiers, in your team's order.

On September 23 your team sent back the priority of prospect roles in three tiers, and this section now reads the way they drew it. The big number on each card is the family total across the full 21,388 census, all seniorities, pre-verification, the same totals as before. The entry band under it applies the rule behind the 4,484 to every family: director and manager level, plus Head titles that carry Director, with your client companies out, confirmed ex-US people held out, and the hubs, agencies and diagnostics firms that share these titles screened out. Four of the roles you named are not families the census holds yet: pharma brand marketing in A, Access Operations in B, and analytics and field sales in C. We pull those fresh in the build, cut to the titles you mean. The families your August ruling cut or parked now sit where your tiers put them: commercial leadership and patient services in B, HEOR in C. The rest of your exclusion list, the names to avoid, is still in progress, and nothing is contacted before it lands and is applied.

Seniority across the 21,388.

Twelve rows from the sweep.

Twelve real people across twelve pharmaceutical and biotech organizations, from Eli Lilly down to a 180-person biotech, with their titles exactly as the estate recorded them. This table did its job on Wednesday: eight of its twelve rows now sit outside the pool your red pen drew, a commercial-leadership VP you cut outright among them, and one row, Jeff Haushalter, turned out to be someone you know and already have on your list to reconnect with. That is what a sample is for.

The 365 rows you scored, matched against the map.

You sent us "Pharma Brands with Pain": 303 in-market brand rows and 62 launches inside the PDUFA window, each scored on your four criteria, access complexity, field capacity, competition, commercial pressure. We matched every row against the map: 321 of the 365 sit at companies where the map already holds named access-family people, 5,903 of them on Wednesday's join, 6,570 once we corrected the company-name read, 2,733 at director level or above. Then we went after the 44 rows with no name. A live sweep through a third licensed source that week named 683 more access-family people, 476 at director or above, across 33 of the 34 companies behind those rows. Combined: 365 of your 365 rows now carry named people, including all 241 Tier 1 rows and all 62 launches. Six rows from the cross-check:

Four of the 683 from the live sweep, titles exactly as recorded:

Your files went straight to work.

First, the census. Overnight we ran your whole market again, this time across everything at once: our estate, two independent licensed sources, and your own Asembia attendee file, deduplicated person by person. The result is the page you are on: 21,388 named people in the access conversation, 17,008 of them at the companies behind your 365 rows, and that at-your-companies figure is a floor because company names hide matches. By your exact rule, directors and managers in the first three rings, the entry pool is 4,868, with a further 1,487 specialists held as the champions layer for your call. All of it pre-verification. Two housekeeping notes we would rather volunteer than have you find: our own earlier join under-read your company names and we have corrected it, and about 2,100 census people are confirmed ex-US and held out of the pools until your therapy-in-market rule is applied person by person.

Hours after the call you sent the transcript and your Asembia attendee file, 6,376 people carrying your own codes. Of the segment you scored best fit, pharma company, score 1, role A, 92 are already on the map. We ran all 92 through an independent licensed source overnight: 76 confirmed still at the company your file lists, 2 now at another company on your brands sheet, and 14 the source did not return, so they stay unverified until crossed elsewhere. The same check also handed us the current employer for 43 of our own records, a re-key that lands in the next pass, which is exactly the job verification exists to do.

The trigger you named, run as a lane. "New hires is a great trigger event", your words, and a new leader creates change anyway. So we ran a first pass overnight: at least 78 people in your first three rings are inside their first year in seat at your target companies, with five brand-new VPs of market access alongside them and a sixth on the boundary. The source's start dates are month-granular, so months are rounded. A sample:

And the signal behind your one dark row, measured at scale. Noven going dark made sense because the company had posted the access seat itself. The same signal runs across your whole list: at least 33 of your target companies have posted market access titled roles, AbbVie, Novartis, Merck, AstraZeneca, Amgen and Takeda among them. How recent each posting is gets dated in the verification pass before anyone treats it as live.

The full market, mapped.

That week's gap-fill run folded straight into the same census, dictionary and logic behind everything above. The numbers below are the ones to work from, still pre-verification, still a floor rather than a ceiling.

Inside the 4,868 entry-strict pool, before your client companies came out, the function split leans the way your own ruling does: Market Access carries 2,495 people, Managed Markets and Payer carries 1,579, and Patient Access carries 794. Together those three functions make up all of that 4,868.

The same rule and the same gate, cut by your September 23 tiers. With your client companies out, the 4,484 is market access 2,303, managed markets and payer 1,432 and patient access 749, so 3,735 of it sits in your A tier and 749 in your B tier. Run the same entry band across every family your tiers bring in and it reads like this, still pre-verification:

Pharma brand marketing in A, Access Operations in B, and analytics and field sales in C, are not in these counts. They come from the fresh pull in the build.

Seniority across the 21,388.

Every one of your companies now carries a name.

Checked company by company against the 365 brand rows on your sheet:

We went looking for what's missing. We found nothing missing.

A fresh discovery pass that week searched specifically for US biopharma manufacturers that fit your profile, a real field team and a market access organization, sitting outside both your list and our census. It surfaced 58 candidate companies, matched 13 of them straight to companies already on the map, and found zero companies genuinely new to either your list or our census.

What we need from you.